

<教科書>

Book

1. **Hirakawa A**, Sato H, Daimon T, Matsui S. *Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted*, Springer. 2018.
2. Daimon T, **Hirakawa A**, Matsui S. *An Introduction to Dose-Finding Methods in Early Phase Clinical Trials*, Springer. 2019

Book chapter

3. **Hirakawa A**, Matsui S. (2014). Dose-finding for two-agent combination phase I trials. *Developments in Statistical Evaluation of Clinical Trials*, Springer.
4. Daimon T, **Hirakawa A**, Matsui S. (2014). Phase I dose-finding designs and their applicability to targeted therapies. *Design and Analysis of Clinical Trials for Predictive Medicine*, CRC Press.
5. **Hirakawa A**, Sato H. (2017) A comparative study of model-based dose-finding methods for two-agent combination trials. *Frontiers of Biostatistical Methods and Applications in Clinical Oncology*, Springer.

翻訳

6. 五所正彦（監訳）．佐藤泰憲，竹内久朗，長島健悟，中水流嘉臣，平川晃弘（共訳），松永信人，山田雅之．生存時間解析入門 [原著第2版]．デビット・ホスマー，スタンリー・レメショウ，スーザン・メイ *Applied Survival Analysis*, 2nd edition. 2014. 東京大学出版会.
7. 西山毅（監訳）．菱田朝陽，中枿昌弘，室谷健太，平川晃弘（共訳）．実践でわかる！Rによる統計遺伝学. *Andrea S. Foulkes*. 2016. 丸善出版.
8. 平川晃弘（監訳）．浅野淳一，上村鋼平，佐藤宏征，木下文恵，武内亜希子（共訳）．臨床試験のためのデータモニタリング委員会：実践ハンドブック．スーザン・エレンバーグ，トーマス・フレミング，デビット・デメッツ．*Data Monitoring Committees in Clinical Trials: A Practical Perspective*. 2017. サイエンティスト社.
9. 平川晃弘，五所正彦（監訳）．臨床試験のためのアダプティブデザイン．2018. 朝倉書店.

<査読付論文>

Statistical Methodologies

1. **Hirakawa A**, Sato Y, Sozu T, Hamada C, Yoshimura I. Estimating the false discovery rate using mixed normal distribution for identifying differentially expressed genes in microarray data analysis. *Cancer Informatics*, 2007; 3: 367-375.
2. **Hirakawa A**, Sato Y, Hamada C, Yoshimura I. A new test statistic based on shrunken sample variance for identifying differentially expressed genes in small microarray experiments. *Bioinformatics and Biology Insights*, 2008; 2: 145-156.
3. Ando Y, **Hirakawa A**, Uyama Y. Adaptive clinical trials for new drug applications in Japan. *European Neuropsychopharmacology*, 2010; 21: 175-179.
4. Ando Y, **Hirakawa A**. Discussion of “Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations”. *Statistics in Biopharmaceutical Research*, 2010; 2: 462-465.
5. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation for a regularized t-statistic in microarray experiments. *Statistics and Probability Letters*, 2011; 81: 870-875.
6. **Hirakawa A**, Hamada C, Yoshimura I. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments. *Journal of Biopharmaceutical Statistics*, 2012; 22: 260-275.
7. Kaneko S, **Hirakawa A**, Hamada C. Gene selection using a high-dimensional regression model with microarrays with cancer prognostic studies. *Cancer Informatics*, 2012; 11: 29-39.
8. **Hirakawa A**. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials. *Statistics in Medicine*, 2012; 31: 516-532.
9. **Hirakawa A**, Hamada C, Matsui S. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials. *Statistics in Medicine*, 2013; 32: 4515-4525.
10. Asano J, **Hirakawa A**, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model with Application to Breast Cancer Data. *Japanese Journal of Biometrics*, 2013; 34: 21-34.
11. **Hirakawa A**, Matsui S. Response to Letter to the Editor by Drs Wages et al. *Statistics in Medicine*, 2014; 33, 2159-60.
12. Asano J, **Hirakawa A**, Hamada C. Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer data. *Pharmaceutical Statistics*, 2014; 13: 357-363.
13. Asakawa T, **Hirakawa A**, Hamada C. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials. *Journal of Biopharmaceutical Statistics*, 2014; 23: 310-325.

14. Kaneko S, **Hirakawa A**, Hamada C. Enhancing the lasso approach for developing a survival prediction model based on gene expression data. *Computational and Mathematical Methods in Medicine*, 2015; 2015: 259474 .
15. Kakurai Y, **Hirakawa A**, Hamada C. A dose-finding method based on multiple dosing in two-agent combination phase I trials. *Journal of Biopharmaceutical Statistics*, 2015; 25: 1065-1076.
16. Murotani K, **Hirakawa A**, Aoyama Y, Yanagawa Y. Follow-u deign for comparing to binary diagnostic. *Austin Biometrics and Biostatistics*, 2015;2: 1016.
17. **Hirakawa A** and Matsui S. Operating characteristics of restrictions on skipping dose level for adaptive dose-finding method in two-agent phase I trials. *Japanese Journal of Biometrics*, 2015; 36:1-12.
18. **Hirakawa A**, Wages NA, Sato H, Matsui S. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies. *Statistics in Medicine*, 2015; 34: 3194-3213.
19. Gosho M, **Hirakawa A**, Maruo K, Noma H, Sato Y. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts. *Statistical Method in Medical Research*, 2015; doi: 10.1177/0962280215597938.
20. **Hirakawa A**, Sato H. Authors' Reply: Response to Letter to the Editor by Drs Riviere et al. *Statistics in Medicine*, 2016; 35: 479-480.
21. Sato H, **Hirakawa A (equal contribution)**, Hamada C. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials. *Statistics in Medicine*, 2016; 35:4093-4109.
22. **Hirakawa A**, Sato H, Gosho M. Effect of design specifications in dose-finding trials for combination therapies in oncology. *Pharmaceutical Statistics*, 2016; 15: 531-540.
23. Gosho M, Maruo K, Ishii R, **Hirakawa A**. Analysis of an incomplete longitudinal composite variable using a marginalized random effects model and multiple imputation. *Statistical Method in Medical Research*, 2016; DOI: 10.1177/0962280216677879.
24. Asano J, **Hirakawa A (equal contribution)**. Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: application to breast cancer data. *Journal of Biopharmaceutical Statistics*, 2017 Feb 13:1-15. doi: 10.1080/10543406.2017.1293082.
25. Shimura M, Gosho M, **Hirakawa A**. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data. *Statistics in Medicine*, 2017; 36:2067-2080.
26. Gosho M, Maruo K, Tada K, **Hirakawa A**. Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. *European Journal of Clinical Pharmacology*, 2017; 73: 779-786.
27. Nomura S, **Hirakawa A**, Hamada C. Sample size determination for the current strategy in

- oncology phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. *Journal of Biopharmaceutical Statistics*, 2017; 8: 1-23.
28. **Hirakawa A**, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, Ueda T, Ozaki T, Tamura K, Kawai A, Fujiwara Y. Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma. *Therapeutic Innovation & Regulatory Science*, 2018; 52:334-338 .
 29. **Hirakawa A**, Yonemori K, Kinoshita F, Kobayashi Y, Okuma H, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Harris PJ, Takebe N. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trial. *Cancer Science*, 2018 ;109:207-214.
 30. Shimamura F, Hamada C, Matsui S, **Hirakawa A (corresponding author)**. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials. *Journal of Biopharmaceutical Statistics*, 2018; 18:1-13.
 31. **Hirakawa A**, Hatakeyama T, Kobayashi D, Nishiyama C, Kada A, Kiguchi T, Kawamura T, Iwami T. Real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests: study protocol for a randomized controlled trial. *Trials*. 2018; 19:510
 32. **Hirakawa A**, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. *Contemporary Clinical Trial Communications*, 2018;12:1-8
 33. Kakurai Y, Kaneko S, Hamada C, **Hirakawa A (corresponding author)**. Dose individualization and variable selection using Bayesian Lasso in early phase dose-finding trials. *Applied Statistics*. 2019; 68:445-460.
 34. Kada A, **Hirakawa A (equal contribution)**, Kinoshita F, Kobayashi Y, Hatakeyama T, Kobayashi D, Nishiyama C, Iwami T. Sample size estimation and re-estimation of cluster randomized controlled trials for real-time feedback, debriefing, and retraining system of cardiopulmonary resuscitation for out-of-hospital cardiac arrests. *Contemporary Clinical Trials Communications*. 2019; 14: 100316.
 35. **Hirakawa A**, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. *Clinical Pharmacology & Therapeutics*. 2019; DOI: 10.1002/pros.23818.

Regulatory Science

36. Yonemori K, **Hirakawa A**, Komiyama N, Kouno T, Ando M, Fujiwara Y, Urano T, Akagawa H, Maruyama H, Toyoshima S. Participation of elderly patients in registration trials for oncology drug applications in Japan. *Annals of Oncology*, 2010; 21: 2112-2118.

37. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Compliance with good clinical practice in oncology registration trials in Japan. *Annals of Oncology*, 2011; 22: 1451-1456.
38. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? *Journal of Geriatric Oncology*, 2011; 2: 25-30.
39. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y. The notorious “drug lag” for oncology in Japan. *Investigational New Drugs*, 2011; 29: 706-712.
40. Yonemori K, **Hirakawa A**, Ryushima Y, Saito M, Yamamoto H, Hirata T, Ando M, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Yamamoto H, Fujiwara. An analysis of guidance for proper usage documents for oncology drugs in Japan. *Pharmaceutical Medicine*, 2012; 26: 165-170.
41. Yonemori K, **Hirakawa A**, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Yasuhiro F. Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal. *PLoS ONE*, 2012; 7: e44393.
42. **Hirakawa A**, Yonemori K, Kuwatsuka Y, Kodaira M, Yamamoto H, Yunokawa M, Hamada A, Shimizu C, Tamura K, Gemma A, Fujiwara Y. A descriptive analysis of post-chemotherapy development of interstitial lung disease using spontaneous reporting data in Japan. *Current Drug Safety*, 2014; 9: 220-226.
43. Yonemori K, **Hirakawa A (equal contribution)**, Kawachi A, Kinoshita F, Ohkuma H, Nishikawa T, Kenji T, Fujiwara Y, Takebe N. Drug induced Interstitial Lung Disease in Oncology Phase I Trials. *Cancer Science*, 2016; 107(12):1830-1836.
44. **Hirakawa A**, Kinoshita F. An analysis of Japanese patients enrolled into multiregional clinical trials in oncology. *Therapeutic Innovation & Regulatory Science*, 2017; 51: 207–211.

Cooperative Clinical and Basic Researches

45. Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, **Hirakawa A**, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. *British Journal of Cancer*, 2008; 100: 50-55.
46. Hirata T, Shimizu C, Yonemori K, **Hirakawa A**, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. *British Journal of Cancer*, 2009; 101: 1529-1536.
47. Yonemori K, Tsuta K, Ono M, Shimizu C, **Hirakawa A**, Hasegawa T, Hatanaka Y, Narita T, Shibui S, Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple

- negative and basal-type breast cancer but not HER2/neu-positive breast cancer. *Cancer*, 2010; 116: 302-308.
48. Yonemori K, Kouno T, Ando M, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y. Influence of suboptimal treatment in patients with mediastinal primary non-seminomatous germ cell tumor. *Oncology*, 2010; 78: 34-39.
 49. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, **Hirakawa A**, Ono M, Kouno T, Katsumata N, Ando M, Tamura K, Hasegawa T, Kinoshita T, Fujiwara Y. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. *Journal of Surgical Oncology*, 2010; 101: 222-227.
 50. Hashimoto K, Yonemori K, Katsumata N, Shimizu C, **Hirakawa A**, Hirata T, Kouno T, Tamura K, Ando M, Fujiwara Y. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. *Annals of Oncology*, 2010; 21: 2195-2200.
 51. Hashimoto K, Yonemori K, Shimizu C, **Hirakawa A**, Yamamoto H, Ono M, Hirata T, Kouno T, Tamura K, Katsumata N, Ando M, Fujiwara Y. A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. *Medical Oncology*, 2011; 28: 434-440.
 52. Yonemori K, Tsuta K, Ando M, **Hirakawa A**, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. Contrasting prognostic implications of platelet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. *Annals of Surgical Oncology*, 2011; 18: 2841-2850.
 53. Hirata T, Yonemori K, Ando M, **Hirakawa A**, Tsuda H, Hasegawa T, Chuman H, Namikawa K, Yamazaki N, Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma. *European Journal of Dermatology*, 2011; 21: 539-545.
 54. Hirata T, Yonemori K, **Hirakawa A**, Shimizu C, Tamura K, Ando M, Katsumata N, Tanimoto M, Fujiwara Y. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. *European Respiratory Journal*, 2011; 38: 1425-1430.
 55. Hashimoto K, Yonemori K, Katsumata N, **Hirakawa A**, Hirata T, Yamamoto H, Shimizu C, Tamura K, Ando M, Fujiwara Y. Use of squamous cell carcinoma antigen as biomarker of chemotherapy response in patients with metastatic cervical carcinoma. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 2011; 159: 394-398.
 56. Hashimoto K, Sasajima Y, Ando M, Yonemori K, **Hirakawa A**, Furuta K, Tsuda H, Fujiwara Y. Immunohistochemical profile for unknown primary adenocarcinoma. *PLoS ONE*, 2012; 7: e31181.
 57. Kojima Y, Hashimoto K, Ando M, **Hirakawa A**, Yonemori K, Kodaira M, Yunokawa M,

- Shimizu C, Tamura K, Katsumata N, Hosono A, Makimoto A, Fujiwara Y. Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. *Journal of Cancer Research and Clinical Oncology*, 2012; 138: 1249-1257.
58. Azuma Y, Hata K, Sai K, Udagawa R, **Hirakawa A**, Tohkin M, Ryushima Y, Makino Y, Yokote N, Fujiwara Y, Saito Y, Yamamoto H. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. *Biological & Pharmaceutical Bulletin*, 2012; 35: 717-724.
59. Tanabe Y, Hashimoto K, Shimizu C, **Hirakawa A**, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. *International Journal of Clinical Oncology*, 2013; 18: 132-138.
60. Sato Y, Kawataki M, **Hirakawa A**, Kato T, Itani T, Hayakawa M. The diameter of the inferior vena cava provides a noninvasive way of calculating central venous pressure in neonates. *Acta Paediatrica*, 2013; 102: e241-e246.
61. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, **Hirakawa A**, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K. Minocycline selectively inhibits M1 polarization of microglia. *Cell Death & Disease*, 2013; 7: e525.
62. Hirano K, Ohgomori T, Kobayashi K, Tanaka F, Matsumoto T, Natori T, Matsuyama Y, Uchimura K, Sakamoto K, Takeuchi H, **Hirakawa A**, Suzumura A, Sobue G, Ishiguro N, Imagama S, Kadomatsu K. Ablation of keratan sulfate accelerates early phase pathogenesis of ALS. *PLoS ONE*, 2013; 25: e66969.
63. Nakamura R, Atsuta N, Watanabe H, **Hirakawa A**, Watanabe H, Ito M, Senda J, Katsuno M, Tanaka F, Izumi Y, Morita M, Ogaki K, Taniguchi A, Aiba I, Mizoguchi K, Okamoto K, Hasegawa K, Aoki M, Kawata A, Abe K, Oda M, Konagaya M, Imai T, Nakagawa M, Tsuji S, Kaji R, Nakano I, Sobue G. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. *Journal of Neurology, Neurosurgery, and Psychiatry*, 2013; 84:1365-1371.
64. Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, **Hirakawa A**, Yokoi K. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the TNM classification of lung cancer. *Journal of Thoracic Oncology*, 2013; 8: 1551-1557.
65. Asano J, **Hirakawa A**, Hamada C, Yonemori K, Hirata T, Shimizu C, Tamura K, Fujiwara Y. Use of Cox's cure model to establish clinical determinants of long-term disease-free survival in breast cancer patients treated with neoadjuvant chemotherapy. *International Journal of Breast*

- Cancer*, 2013; 354579.
66. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, Sakao Y, Mitsudomi T, **Hirakawa A**, Yokoi K. Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small cell lung cancer. *European Journal of Cardio-Thoracic Surgery*, 2014; 45: 687-692.
 67. Goto M, Yamamoto T, Kato M, Majima T, Toriyama K, kamei Y, Matsukawa Y, **Hirakawa A**, Funahashi Y. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients. *International Journal of Urology*, 2014; 21: 294-300.
 68. Arima H, Wakabayashi T, Nagatani T, Fujii M, **Hirakawa A**, Murase T, Yambe Y, Yamada T, Yamakawa F, Yamamori I, Yamaguchi M, Oiso Y. Adipsia increases risk of death in patients with central diabetes insipidus. *Endocrine Journal*, 2014; 61:143-148.
 69. Yamada S, **Hirakawa A**. Reply to: appropriate statistical descriptions for evaluating the predictive role of epithelial-to-mesenchymal transition in patients with pancreatic cancer. *Surgery*, 2014; 155: 959-960.
 70. Harano K, **Hirakawa A**, Kato T, Suzuki K, Watanabe S, Katsumata N. Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan. *Journal Gynecologic Oncology*, 2014; 25: 124-129.
 71. Taniyama TK, Hashimoto K, Katsumata, N, **Hirakawa A**, Yonemori K, Yunokawa M, Shimizu C, Tamura K, Ando M, Fujiwara Y. Can oncologists predict survival for patients with progressive disease after standard chemotherapies? *Current Oncology*, 2014; 21: 84-90.
 72. Ozeki N, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, **Hirakawa A**, Yokoi K. Therapeutic surgery without a definitive diagnosis can be an option in selected patients with suspected lung cancer. *Interactive Cardiovascular Thoracic Surgery*, 2014; 5:830-837.
 73. Kataoka Y, Nishida S, **Hirakawa A**, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. *Endocrine Journal*, 2015; 62: 195-200.
 74. Watanabe H, Atsuta N, Nakamura R, **Hirakawa A (equal contribution)**, Watanabe H, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 2015; 16: 230-236.
 75. Tsuda H, Kotani T, Sumigama S, Mano Y, Kawabata I, Takahashi Y, Iwagaki S, **Hirakawa A**, Kikkawa F. Amniotic lamellar body count: predicting and distinguishing neonatal respiratory

- complications in twin pregnancies. *Clinica Chimica Acta*, 2015; 441: 75-78.
76. Kato T, Iwano S, Taniguchi T, Kawaguchi K, Fukui T, Ishiguro F, Fukumoto K, Nakamura S, **Hirakawa A**, Yokoi K. The contact length between the tumor contour and the lung on computed tomography is a risk factor for pleural recurrence after complete resection of thymoma. *General Thoracic and Cardiovascular Surgery*, 2015; 63: 343-348.
77. Hattori T, Sato Y, Kondo T, Ichinohashi Y, Sugiyama Y, Yamamoto M, Kotani T, Hirata H, **Hirakawa A**, Suzuki S, Tsuji M, Ikeda T, Nakanishi K, Kojima S, Blomgren K, Hayakawa M. Administration of umbilical cord blood cells transiently decreased hypoxic-ischemic brain injury in neonatal rats. *Developmental Neuroscience*, 2015; 37: 95-104.
78. Okada N, Tajima K, Takami Y, Kato W, Kei F, Hibino M, Munakata H, Sakai Y, **Hirakawa A**, Usui A. Valve selection for the aortic position in dialysis patients. *The Annals of Thoracic Surgery*; 2015; 99: 1524-1531.
79. Hashizume A, Katsuno M, Suzuki K, Banno H, Suga N, Mano T, Araki A, Hijikata Y, Grunseich C, Kokkinis A, **Hirakawa A**, Watanabe H, Yamamoto M, Fischbeck KH, Sobue G. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study, *Neuromuscular Disorders*, 2015; 25: 554-562.
80. Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, **Hirakawa A**, Yokoi K. Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma? *Lung Cancer*, 2015; 89: 38-42.
81. Suzuki N, Takedani H, **Hirakawa A**, Ushijima Y, Matsushita T. The features of clearance in recombinant factor IX (BeneFIX®). *Haemophilia*, 2015; 21: 702-707
82. Tsuda H, **Hirakawa A**, Kotani T, Sumigama S, Mano Y, Nakano T, Imai K, Kawabata I, Takahashi Y, Iwagaki S, Kikkawa F. Risk assessment for neonatal RDS/TTN using gestational age and the amniotic lamellar body count in twin pregnancies. *Clinica Chimica Acta*. 2015; 451: 301-304.
83. Harano K, **Hirakawa A**, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. *International Journal of Clinical Oncology*, 2016; 21: 168-176.
84. Nakano T, Kotani T, Mano Y, Tsuda H, Imai K, Ushida T, Li H, Miki R, Sumigama S, Sato Y, Iwase A, **Hirakawa A**, Asai M, Toyokuni S, Kikkawa F. Maternal molecular hydrogen administration on lipopolysaccharide-induced mouse fetal brain injury. *Journal of Clinical Biochemistry and Nutrition*, 2015; 57: 178-182.
85. Harano K, Yonemori K, **Hirakawa A**. The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study. *Breast Cancer*, 2016; 23: 797-806.

86. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, **Hirakawa A**, Tateyama H, Yokoi K. Prognostic impact of tumour size in completely resected thymic epithelial tumours. *European Journal of Cardio-Thoracic Surgery & Interactive Cardiovascular and Thoracic Surgery*, 2016; 49: 574-579.
87. Watanabe H, Atsuta N, **Hirakawa A (equal contribution)**, Nakamura R, Nakatochi M, Ishigaki S, Iida A, Ikegawa S, Kubo M, Yokoi D, Watanabe H, Ito M, Katsuno M, Izumi Y, Morita M, Kanai K, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Kawata A, Aoki M, Tsuji S, Nakashima K, Kaji R, Sobue G. A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. *Journal of Neurology, Neurosurgery, and Psychiatry*. 2016; 87: 851-858.
88. Imai K, Kotani T, Tsuda H, Mano Y, Nakano T, Ushida T, Li H, Miki R, Sumigama S, Iwase A, **Hirakawa A**, Ohno K, Toyokuni S, Takeuchi H, Mizuno T, Suzumura A, Kikkawa F. Neuroprotective potential of molecular hydrogen against perinatal brain injury via suppression of activated microglia. *Free Radical Biology & Medicine*. 2016; 91: 154-163.
89. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, **Hirakawa A**, Gotoh M. The Change of Testosterone Secretion During the Treatment of Alpha-1 Blocker in Patients with Benign Prostatic Hyperplasia. *Urology*. 2016; 88: 149-154.
90. Kato M, Tsuzuki T, Kimura K, **Hirakawa A**, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori R, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. *Modern Pathology*. 2016; 29: 166-73.
91. Tanaka R, Yonemori K, **Hirakawa A**, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Risk factors for developing skeletal-related events in breast cancer patients with bone metastases undergoing treatment with bone-modifying agents. *Oncologist*. 2016; 21: 508-513.
92. Shimada K, Shimada S, Sugimoto K, Nakatochi M, Suguro M, **Hirakawa A**, Hocking TD, Takeuchi I, Tokunaga T, Takagi Y, Sakamoto A, Aoki T, Naoe T, Nakamura S, Hayakawa F, Seto M, Tomita A, Kiyoi H. Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma. *Leukemia*, 2016; 30: 1568-1579.
93. Yamada S, Fujii T, **Hirakawa A**, Kanda M, Sugimoto H, Kodera Y. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. *Langenbeck's Archives of Surgery*. 2016; 401(8):1143-1152
94. Nagata T, Sobajima H, Ohashi N, **Hirakawa A**, Katsuno T, Yasuda Y, Matsuo S, Tsuboi N, Maruyama S. Association between 24h Urinary Sodium and Potassium Excretion and Estimated Glomerular Filtration Rate (eGFR) Decline or Death in Patients with Diabetes Mellitus and eGFR More than 30 ml/min/1.73m². *PLOS ONE*, 2016; 11: e0152306.

95. Harano K, **Hirakawa A**, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, Aoki D, Ito K, Ito K, Nakanishi T, Susumu N, Takehara K, Watanabe Y, Watari H, Saito T. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. *Gynecologic Oncology*, 2016; 141: 447-453.
96. Yokoi D, Atsuta N, Watanabe H, Nakamura R, **Hirakawa A**, Ito M, Watanabe H, Katsuno M, Izumi Y, Morita M, Taniguchi A, Oda M, Abe K, Mizoguchi K, Kano O, Kuwabara S, Kaji R, Sobue G; JaCALS. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. *Journal of Neurology*, 2016; 263: 1129-1136.
97. Okuma H, Koizumi F, **Hirakawa A**, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. *British Journal of Cancer*, 2016; 115: 411-419.
98. Atsuta Y, **Hirakawa A**, Nakasone H, Kurosawa S, Oshima K, Sakai R, Ohashi K, Takahashi S, Mori T, Ozawa Y, Fukuda T, Kanamori H, Morishima Y, Kato K, Yabe H, Sakamaki H, Taniguchi S, Yamashita T. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, 2016; 22: 1702-1709.
99. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Iida M, Noda S, Nakanishi H, Banno H, Mano T, **Hirakawa A**, Adachi H, Watanabe H, Yamamoto M, Sobue G. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. *Annals of Clinical and Translational Neurology*. 2016; 3: 537-546.
100. Suzuki N, **Hirakawa A**, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, Matsushita T. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. *Haemophilia*, 2017; 23(2):215-221.
101. Kato T, Tsunekawa T, Motoji Y, **Hirakawa A**, Okawa Y, Tomita S. The side-to-side fashion for individual distal coronary anastomosis using venous conduit. *Heart and Vessels*, 2017; 32(4):385-389.
102. Yamasaki S, **Hirakawa A**, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. *Annals of Hematology*, 2017; 96(2):289-297.
103. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, Kawai K, Noda S, Nakanishi H, Banno H, **Hirakawa A**, Koike H, Halievski K, Jordan CL, Katsuno M, Sobue G.

- Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. *PLoS One*. 2016;11(12):e0168846.
104. Imai K, Kotani T, Tsuda H, Nakano T, **Hirakawa A**, Kikkawa F. A Novel Approach to Detecting Postpartum Hemorrhage Using Contrast-Enhanced Ultrasound. *Ultrasound in medicine and biology*. 2017; 43(3):615-620
 105. Kato T, Tamaki M, Tsunekawa T, Motoji Y, **Hirakawa A**, Okawa Y, Tomita S. Health-Related Quality of Life Prospectively Evaluated by the 8-item Short Form After Endovascular Repair Versus Open Surgery for Abdominal Aortic Aneurysms. *Heart vessels*. 2017; . doi: 10.1007/s00380-017-0956-9.
 106. Nakanishi K, Sato Y, Mizutani Y, Ito M, **Hirakawa A**, Higashi Y. Rat umbilical cord blood cells attenuate hypoxic-ischemic brain injury in neonatal rats. *Scientific Reports*. 2017;7:44111.
 107. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, **Hirakawa A**, Wakabayashi T. Hands-on simulation versus traditional video-learning in teaching microsurgery technique. *Neurologia medico-chirurgica*, 2017; 57:238-245.
 108. Ozeki N, Kawaguchi K, Fukui T, Fukumoto K, Nakamura S, Hakiri S, Kato T, **Hirakawa A**, Okasaka T, Yokoi K. The diffusing capacity of the lung for carbon monoxide is associated with the histopathological aggressiveness of lung adenocarcinoma, *European Journal of Cardio-Thoracic Surgery*, 2017;0:1-6. doi:10.1093/ejcts/ezx124.
 109. Hashizume A, Katsuno M, Suzuki K, **Hirakawa A**, Hijikata Y, Yamada S, Inagataki T, Banno M, Sobue G. Long-term treatment with leuporelin for spinal and bulbar muscular atrophy -Natural history-controlled study- *Journal of Neurology, Neurosurgery, and Psychiatry*, 2017; 88: 1026-1032.
 110. Hyodo R, Sato Y, Ito M, Sugiyama Y, Ogawa C, Kawai H, Nakane T, Saito A, **Hirakawa A**, Kidokoro H, Natsume J, Hayakawa M. Magnetic resonance spectroscopy in preterm infants: association with neurodevelopmental outcomes. *Archives of Disease in Childhood.*, 2017; doi: 10.1136/archdischild-2016-311403.
 111. Kawase Y, Tanigaki T, **Hirakawa A**, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Matsuo H. Frequency of a large drift caused by pressure wire using optical fibers. *Cardiovascular Intervention and Therapeutics.*, 2017; doi: 10.1007/s12928-017-0481-x.
 112. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, **Hirakawa A**, Ratanachu-ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone versus the combination. *Endoscopy International Open*, 2017; 5: E1136-E1143.
 113. Yokoi A, Yoshioka Y, **Hirakawa A**, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K,

- Kajiyama H, Kikkawa F, Ochiya T. A combination of circulating miRNAs for the early detection of ovarian cancer. *Oncotarget.*, 2017; 8: 89811-89823.
114. Shimizu S, Yamamoto T, Nakayama S, **Hirakawa A**, Kuwatsuka Y, Funahashi Y, Matsukawa Y, Takanari K, Toriyama K, Kamei Y, Narimoto K, Yamanishi T, Ishizuka O, Mizuno M, Gotoh M. Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol. *BMC Urology.*, 2017; 17: 89.
115. Kato M, Kimura K, **Hirakawa A**, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y1, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T. Prognostic parameter for high risk prostate cancer patients at initial presentation. *Prostate*, 2018; 78: 11-16.
116. Kawase Y, Kawasaki M, Tanigaki T, Omori H, Hirata T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, **Hirakawa A**, Suzuki T, Matsuo H. Postocclusion hyperemia for fractional flow reserve after percutaneous coronary intervention. *Circulation: Cardiovascular Interventions*, 2017; 10. doi: 10.1161/CIRCINTERVENTIONS.117.005674.
117. Ogawa C, Kidokoro H, Fukasawa T, Yamamoto H, Ishihara N, Ito Y, Sakaguchi Y, Okai Y, Ohno A, Nakata T, Azuma Y, Hattori A, Kubota T, Tsuji T, Hirakawa A, Kawai H, Natsume J. Cytotoxic edema at onset in West syndrome of unknown etiology: a longitudinal DTI study. *Epilepsia*, 2018; doi: 10.1111/epi.13988.
118. Ozeki N, Fukui T, Kawaguchi K, Nakamura S, Hakiri S, Kato T, Hirakawa A, Yokoi K. A survival analysis using physique-adjusted tumor size of non-small cell lung cancer. *International Journal of Clinical Oncology*, 2017; doi: 10.1007/s10147-017-1219-6.
119. Sawamura A, Okumura T, Hirakawa A, Ito M, Ozaki Y, Ohte N, Amano T, Murohara T; CHANGE PUMP Investigators. Early Prediction Model for Successful Bridge to Recovery in Patients With Fulminant Myocarditis Supported With Percutaneous Venoarterial Extracorporeal Membrane Oxygenation - Insights From the CHANGE PUMP Study. *Circulation Journal*, 2017; doi: 10.1253/circj.CJ-17-0549.
120. Miyamoto K, Ohkawara B, Ito M, Masuda A, Hirakawa A, Sakai T, Hiraiwa H, Hamada T, Ishiguro N, Ohno K. Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/ β -catenin signaling. *PLoS One*. 2017; 12: e0184388.
121. Miyauchi R, Itoh Y, Kawamura M, Hirakawa A, Shibata K, Kajiyama H, Nakahara R, Kubota S, Ito J, Okada T, Kikkawa F, Naganawa S. Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer. *Nagoya J Med Sci*. 2017 Feb;79(2):211-220. doi: 10.18999/nagjms.79.2.211.
122. Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, Inagaki T, Ito D, Hirakawa A, Kinoshita F, Goshō M, Sobue G. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: study protocol for a randomized, double-blind, placebo-controlled

- trial. *JMIR Res Protoc*. 2018 ;7(3):e69.
123. Hijikata Y, Hashizume A, Yamada S, Inagaki T, Ito D, Hirakawa A, Suzuki K, Atsuta N, Tsuboi T, Hattori M, Horii A, Banno H, Sobue G, Katsuno M. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. *Neurology*. 2018; 90(17):e1501-e1509.
 124. Kawase Y, Kawasaki M, Kikuchi J, Hirata T, Okamoto S, Tanigaki T, Omori H, Ota H, Okubo M, Kamiya H, Hirakawa A, Matsuo H. Residual pressure gradient across the implanted stent: An important factor of post-PCI physiological results. *Journal of Cardiology*. 2018 May;71(5):458-463..
 125. Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K. Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group. *European Journal of Cardio-Thoracic Surgery*. 2016; 49: 574-579.
 126. Ogawa C, Sato Y, Suzuki C, Mano A, Tashiro A, Niwa T, Hamazaki S, Tanahashi Y, Suzumura M, Hayano S, Hayakawa M, Tsuji T, Hoshino S, Sugiyama Y, Kidokoro H, Kawada JI, Muramatsu H, Hirakawa A, Ando M, Natsume J, Kojima S. Treatment with silver nitrate versus topical steroid treatment for umbilical granuloma: a non-inferiority randomized control trial. *PLOS ONE*. 2018;13(2):e0192688.
 127. Imai K, Kotani T, Nakano T, Ushida T, Hirakawa A, Kikkawa F. Maternal protein S activity is associated with massive hemorrhage during Caesarean section: Retrospective case-control study. *The Journal of Maternal-Fetal & Neonatal Medicine (IJMF)*. 2018 Feb 28:1-5.
 128. Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial. *J Neurol Neurosurg Psychiatry*. 2018; pii: jnnp-2018-317964. doi: 10.1136/jnnp-2018-317964.
 129. Goto T, Murata M, Terakura S, Nishida T, Adachi Y, Ushijima Y, Shimada K, Ishikawa Y, Hayakawa F, Nishio N, Nishiwaki S, **Hirakawa A**, Kato K, Takahashi Y, Kiyoi H. Phase I study of cord blood transplantation with intra-bone marrow injection of mesenchymal stem cells: A clinical study protocol. *Medicine*. 2018; 97(17):e0449.
 130. Tanaka R, Yonemori K, **Hirakawa A**, Kinoshita F, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y. Anti-cancer agent-induced life-threatening skin toxicities: A database study of spontaneous reporting data. *The Oncologist*. 2019; 24:266-272.
 131. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, **Hirakawa A**, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The rate of neonatal respiratory distress syndrome/transient tachypnea in

- the newborn and the amniotic lamellar body count in twin pregnancies compared with singleton pregnancies. *Clinica Chimica Acta*. 2018; 484: 293-297.
132. Tsuda H, Kotani T, Nakano T, Imai K, Ushida T, **Hirakawa A**, Kinoshita F, Takahashi Y, Iwagaki S, Kikkawa F. The impact of fertility treatment on the neonatal respiratory outcomes and amniotic lamellar body counts in twin pregnancies. *Clinica Chimica Acta*. 2018; 484: 192-196.
133. Sakamoto Y, Okamoto S, Shimizu K, Araki Y, **Hirakawa A**, Wakabayashi T. Comparative Prospective Study of Microvascular Anastomosis Training by Self-Learning or with Expert Instruction. *World neurosurgery*. 2018; 118: e818-e824.
134. Kato M, **Hirakawa A**, Kobayashi Y, Yamamoto A, Ishida R, Kamihira O, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. Integrating Tertiary Gleason Pattern 5 into the ISUP Grading System Improves Prediction of Biochemical Recurrence in Radical Prostatectomy Patients. *Modern Pathology*. 2019; 32:122-127.
135. Kawamura I, Kajiura R, Motoji Y, Okamoto S, Tanigaki T, Omori H, Hirata T, Kikuchi J, Ota H, Sobue Y, Miyake T, Tsunekawa T, Kato T, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Tomita S, **Hirakawa A**, Kondo T, Suzuki T, Matsuo H. Diagnostic Performance of the Simultaneous Acquisition Rest 99mTc-Tetrofosmin/Stress 201Tl Dual Isotope Protocol with a Semiconductor Camera: Comparison with the Rest-Stress 99mTc-Tetrofosmin Protocol. *Circulation Journal*. 2018; 82: 2837-2844.
136. Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kinoshita F, Nakatochi M, Kobayashi Y, **Hirakawa A**, Nakamura T, Katsuno M. Study protocol for the MEXiletine hydrochloride administration trial: A placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). *BMJ Open*. 2018, 8:e023041.
137. Saji N, Sakurai T, Ito K, Tomimoto H, Kitagawa K, Miwa K, Tanaka Y, Kozaki K, Kario K, Eto M, Suzuki K, Shimizu A, Niida S, **Hirakawa A**, Toba K; Strawberry study investigators. Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study). *BMJ Open*. 2018; 8:e021759.
138. Sato Y, Ueda K, Kondo T, Hattori T, Mikrogeorgiou A, Sugiyama Y, Suzuki T, Yamamoto M, Hirata H, **Hirakawa A**, Nakanishi K, Tsuji M, Hayakawa M. Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats. *Frontiers in Neurology*. 2018; 9: 987.
139. Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, **Hirakawa A**, Michimae H, Hamada A, Yoshida T,

- Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. *European Journal Of Cancer*. 2019; 109: 84-91.
140. Sato et al. Design of a prospective multicenter randomized controlled trial evaluating the effects of gastric lavage on coffee-ground emesis in neonates: study protocol. *Nagoya Journal of Medical Science*.
141. Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, **Hirakawa A**, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. *Neurology*. 2019; 92: e1868-e1877.
142. Taniguchi A, Kawada JI, Go K, Fujishiro N, Hosokawa Y, Maki Y, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Muramatsu H, Kidokoro H, Kinoshita F, **Hirakawa A**, Takahashi Y, Sato Y, Natsume J. Comparison of clinical characteristics of human metapneumovirus and respiratory syncytial virus infection in hospitalized young children. *Japanese Journal of Infectious Diseases*. 2019; doi: 10.7883/yoken.JJID.2018.480.
143. Kato M, **Hirakawa A**, Kobayashi Y, Yamamoto A, Ishida R, Sano T, Kimura T, Majima T, Ishida S, Funahashi Y, Sassa N, Fujita T, Matsukawa Y, Yamamoto T, Hattori R, Gotoh M, Tsuzuki T. The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. *Prostate*. 2019; doi: 10.1002/pros.23818.
144. Shimizu S, Tsuchiya S, **Hirakawa A**, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H. Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol. *BMC Oral Health*. 2019; 19:69.
145. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, **Hirakawa A**, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. *Translational Psychiatry*. 2019; 9:126.
146. Yoshimi A, Yamada S, Kunimoto S, Aleksic B, **Hirakawa A**, Ohashi M, Matsumoto Y, Hada K, Itoh N, Arioka Y, Kimura H, Kushima I, Nakamura Y, Shiino T, Mori D, Tanaka S, Hamada S, Noda Y, Nagai T, Yamada K, Ozaki N. Author Correction: Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. *Translational Psychiatry*. 2019; 9:146.
147. Hashizume A, Katsuno M, Suzuki K, Banno H, Takeuchi Y, Kawashima M, Suga N, Mano T,

- Araki A, Hijikata Y, **Hirakawa A**, Sobue G; JASMITT study group. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. *Journal of Neurology*. 2019; 266:1211-1221.
148. Hirata T, Tanigaki T, Kawase Y, **Hirakawa A**, Omori H, Okamoto S, Ota H, Sobue Y, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Pijls NHJ, Matsuo H. Post-occlusion hyperemia for fractional flow reserve assessment and pull-back curve analysis. *Cardiovascular Intervention and Therapeutics*. 2019; doi: 10.1007/s12928-019-00579-9.
149. Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, Kishimoto Y, Moriyoshi H, **Hirakawa A**, Katsuno M. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. *J Neurol*. 2019 Aug 27. doi: 10.1007/s00415-019-09507-6. [Epub ahead of print]

<査読付論文>

Review

1. 平川晃弘, 松井茂之. がん第 I 相試験における 2 剤併用療法の用量探索法: 最近の展開. *計量生物学*, 2013; 34: 81-97.
2. 平川晃弘, 浅野淳一, 佐藤宏征, 手良向聡. マスタープロトコルに基づくがん臨床試験. *計量生物学*, 2019; 39: 85-101.
3. 平川晃弘, 浅野淳一, 佐藤宏征, 橋本大哉, 手良向聡. がん臨床試験におけるベイズ流バスケットデザインの理論と実装. *計量生物学*, 2019; 39: 103-122.

Regulatory Science

4. 安藤友紀, 平川晃弘. サロゲートエンドポイントの課題と展望〜薬事行政の立場から〜. *医薬ジャーナル*, 2011; 47: 73-75.
5. 斉藤真理, 龍島靖明, 米盛勸, 平川晃弘, 文靖子, 西垣玲奈, 牧野好倫, 岩瀬治雄, 安藤正志, 藤原康弘, 林憲一. 製薬企業発行の抗悪性腫瘍薬剤患者説明用パンフレットの現状調査. *日本病院薬剤師会雑誌*, 2015; 51: 877-881.
6. 平川晃弘, 木下文恵, 森由美子, 清水忍. 抗悪性腫瘍薬の臨床データパッケージ分析からみる今後の課題. *医薬品医療機器レギュラトリーサイエンス*, 2015; 46: 714-720.

Cooperative Clinical and Basic Researches

7. 伊藤祐史, 三浦清邦, 原紳也, 岸本泰明, 平川晃弘, 小川千香子, 城所博之, 奥村直哉, 梶田光春, 夏目淳. 重度肢体不自由児の救急外来受診と入院医療. *日本小児科学会雑誌*. 2016; 120: 356-366.
8. 小川 千香子, 三浦 清邦, 伊藤 祐史, 城所 博之, 平川 晃弘, 根来 民子, 夏目 淳. 重

症心身障害児を持つ親の離婚. *日本小児科学会雑誌*. 2017; 121:563.

9. 大熊ひとみ, ほか. MASTER KEY プロジェクト-希少がんに対するレジストリ・バスケット臨床研究. *腫瘍内科*, 2019; 22:435

受賞歴等

2014 年 Mansfield-PhRMA Research Scholars Program

2016 年 日本計量生物学会 奨励賞

ESMO 2019 MERIT AWARD (共著者)